ResMed Mulls Partners
Apr 2 14
ResMed Inc. (NYSE:RMD) is seeking partners. ResMed is now looking for an electronics partner to work with to produce the devices, which will not require a prescription to buy, Mick Farrell, Chief Executive Officer of ResMed, said, The Australian Financial Review reported.
ResMed Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 12:10 PM
Mar 19 14
ResMed Inc. Presents at 13th Annual Needham Healthcare Conference, Apr-08-2014 12:10 PM. Venue: The Westin Grand Central Hotel, New York, New York, United States.
ResMed Inc. Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-13-2014 08:00 AM
Mar 9 14
ResMed Inc. Presents at Barclays Capital 2014 Global Healthcare Conference, Mar-13-2014 08:00 AM. Venue: Loews Miami Beach Hotel, Miami, Florida, United States.
Apex Embarks on Counter Actions Against ResMed in Europe
Feb 19 14
Apex Medical Corporation announced at a press conference held on February 19, 2014 in Dusseldorf, Germany, that it has initiated challenges to four ResMed patents before the EPO and the German Federal Patent Court as well as the German Patent and Trade Mark Office. The ResMed patents being challenged include those ResMed asserted against Apex in Germany in November 2013. The actions started in Europe are subsequent to Apex's assault launched in August 2013 in the United States on several ResMed patents, which ResMed relied upon to sue competitors such as Apex and other manufacturers. Apex requested the U.S. Patent and Trademark Office to reconsider and reexamine the validity of 6 U.S. patents of ResMed through the 'inter partes' review process. The cases are currently pending before USPTO.
ResMed Inc. Reports Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended December 31, 2013; Provides Effective Tax Rate Guidance for the Fiscal Year 2014
Jan 23 14
ResMed Inc. reported unaudited consolidated earnings results for second quarter and six months ended December 31, 2013. For the quarter, the company’s net revenue was $384,341,000 against $376,537,000 a year ago. Income from operations was $105,020,000 against $92,070,000 a year ago. Income before income tax was $109,461,000 against $98,400,000 a year ago. Net income was $86,636,000 against $77,942,000 a year ago. Diluted earnings per share were $0.60 against $0.53 a year ago. Cash flow from operations was $84.2 million for the quarter, reflecting strong underlying earnings and working capital management. Capital expenditure for the quarter was $19.7 million, while depreciation and amortization for the December quarter totaled $18.6 million.
For the six months, the company’s net revenue was $742,003,000 against $716,269,000 a year ago. Income from operations was $201,903,000 against $172,558,000 a year ago. Income before income tax was $211,530,000 against $189,301,000 a year ago. Net income was $167,566,000 against $149,207,000 a year ago. Diluted earnings per share were $1.15 against $1.02 a year ago. The company disappointed with the US numbers, the two key issues, as it have previously noted, are market restructuring due to competitive bidding and increased competitor activity.
The company currently estimates effective tax rate for fiscal year 2014 will also be in the vicinity of 21%.